How is a business valued for investment?

Pre-money valuation is the agreed or assessed value of the company’s equity immediately before a new investment. Post-money valuation is that value plus the money subscribed for newly issued shares. Both are equity concepts: neither should be confused with enterprise value, which describes the value of the operating business before the relevant adjustments for debt, cash and other claims. Establishing which number everyone is discussing prevents avoidable misunderstandings.

In a hypothetical straightforward transaction, a company with a £4 million pre-money equity valuation raises £1 million through new ordinary shares. Its headline post-money valuation is £5 million, and the investor receives 20% of the enlarged share capital. That calculation assumes equivalent share rights, no other simultaneous share issues or conversions, and a clearly agreed definition of the share capital used to calculate the subscription price.

Money paid to an existing shareholder is different. A secondary purchase transfers ownership but does not put fresh cash into the company. Where a funding round combines a new share subscription with a sale by founders, the two elements need separating. Otherwise, a headline announcement about the amount invested can overstate the cash available to finance the business and obscure the ownership calculation.

Post-money arithmetic is not an independent demonstration of value. It describes the structure of the transaction once its pricing and assumptions have been established. For a formal valuation, the purpose, valuation date, basis of value and interest being valued must also be clear. Transaction expenses and the actual cash available after completion should be shown separately rather than silently mixed into the headline terminology.

Reference framework:[1] IVSC[4] IPEV[5] ICAEW

Investors usually begin with the economic proposition: what generates customer demand, how reliably that demand converts into cash, and whether the business can grow without consuming disproportionate capital. Historical accounts provide a starting point, but current trading and the credibility of the plan are equally important. A valuation should explain the connection between the commercial evidence and the financial assumptions rather than simply attach a multiple to management’s preferred forecast.

For an established profitable company, sustainable earnings and relevant market evidence may provide a useful framework. For another business, cash-flow analysis or an asset-based assessment may be more informative. The appropriate approach depends on the business, available evidence and valuation purpose. Cross-checks are helpful, but averaging incompatible outputs does not resolve differences in assumptions or improve weak underlying information.

Comparability requires particular care. A quoted company or disclosed acquisition may differ in size, growth, margins, customer concentration, geography and access to finance. A control acquisition may also incorporate benefits unavailable to a new minority investor. Market evidence therefore needs interpretation: a reported multiple cannot simply be transferred to a private company because both businesses operate in the same broad sector.

The amount the company wants to raise is not itself evidence of its existing value. Nor does a founder’s preferred dilution establish a defensible pre-money valuation. Those preferences help frame the negotiation, but the valuation must work back to commercial prospects, financial risk and the proposed rights. An assessment that exposes a funding gap can be more useful than one engineered to reproduce the desired percentage.

Reference framework:[1] IVSC[4] IPEV[5] ICAEW

A company does not need current profits to have value, but the absence of established earnings changes the evidence required. Investors need to understand what has already been demonstrated and what remains speculative. Evidence may include paying customers, retention, contracted revenue, product readiness, ownership of intellectual property and a credible route to positive cash generation. A large potential market alone does not establish the company’s ability to capture it profitably.

Forecasts should distinguish the existing position from outcomes dependent on new investment. If the plan requires additional people, product development or market entry, the associated expenditure and execution risk belong in the analysis. Growth cannot be treated as certain while the cost of achieving it is omitted. Working-capital requirements, capital expenditure and the timing of receipts can materially change the funding needed to reach the next milestone.

Scenario analysis is often more informative than a single confident forecast. A valuation can examine what happens if customer acquisition is slower, margins improve later, or development takes longer than expected. The objective is not to produce an exhaustive list of disasters, but to identify the assumptions that drive value and liquidity. Risks should be reflected coherently, avoiding unexplained duplication across forecasts, probabilities and discount rates.

Future fundraising also matters. An investor may acquire a stake today that will be diluted before the company becomes self-financing or reaches an exit. The analysis should distinguish value attributable to the existing business from value dependent on future capital and successful execution. Any use of milestones, probability weightings or expected exit proceeds should make the underlying assumptions visible rather than imply that a speculative outcome is assured.

Reference framework:[1] IVSC[4] IPEV

A recent investment by an informed, independent investor can be important valuation evidence. It reflects an actual commitment of capital rather than an asking price or informal expression of interest. Nevertheless, its relevance depends on the circumstances: the transaction date, the information available, the investor’s relationship with the company, the funding conditions and the precise security purchased all need to be understood.

The IPEV Valuation Guidelines provide a useful framework for considering investment transactions and calibrating valuation inputs. Calibration means checking how a valuation approach relates to the transaction evidence and its assumptions. It does not mean keeping the last round’s valuation unchanged indefinitely. Subsequent trading, market conditions, financing needs and progress against milestones may support a different conclusion at a later valuation date.

An insider-led round, urgent bridge financing or investment with substantial downside protection may not provide the same evidence as a broadly negotiated ordinary-share subscription. Such transactions should not automatically be rejected, but their circumstances require analysis. Equally, an unsigned term sheet or a conditional offer is not equivalent to a completed investment. The strength of the evidence should be stated rather than assumed.

A fundraising valuation also should not automatically be reused for tax, employee share awards or financial reporting. Different purposes can involve different statutory rules, valuation bases and securities. For example, a statutory market-value assessment under TCGA 1992 section 272 addresses a hypothetical open-market sale, not merely the price founders hope to negotiate. The appropriate tax or accounting framework must be identified separately before relying on the funding round.

Reference framework:[1] IVSC[4] IPEV[2] TCGA 1992, section 272[6] FRC

An investor’s percentage ownership is only one part of the economic bargain. Ordinary shares, preference shares and convertible instruments may participate differently in dividends, sale proceeds and downside outcomes. Where the investor receives rights unavailable to founders, applying the investor’s price per share to every existing share can give a misleading impression of value. The valuation needs to identify the relevant classes and understand how their rights interact.

Liquidation preferences illustrate the issue. Depending on the documents, an investor may recover an agreed amount before ordinary shareholders participate, or may choose between a preference entitlement and conversion into ordinary shares. Participation rights and preference ranking can change the allocation further. The wording matters: labels such as ‘preferred equity’ are insufficient to establish how proceeds would actually be distributed.

Option pools can alter founder dilution without changing the headline investment amount. In a hypothetical transaction where the investor receives 20% and an unallocated option pool represents 10% of the fully diluted post-investment capital, existing shareholders collectively retain 70%, assuming no other interests. Whether that pool is created within the pre-money capitalisation or through another arrangement affects who bears the dilution and should be settled explicitly.

Convertible loans, subscription agreements for future equity, warrants and outstanding options also require a clear treatment. The cap table should show the contractual conversion or exercise assumptions rather than count only shares currently issued. Voting controls, consent rights and transfer provisions should be reviewed alongside economic rights. Solicitors interpret and document those provisions; the valuer considers their implications for the interest being valued.

Reference framework:[1] IVSC[4] IPEV[5] ICAEW

Not necessarily. A higher pre-money valuation may be accompanied by stronger investor preferences, more extensive controls or conditions that make funding less certain. A lower headline valuation with simpler rights and sufficient committed capital may produce a better outcome for existing shareholders in some circumstances. Comparing offers therefore requires both a capitalisation analysis and an assessment of how proceeds would be shared under different outcomes.

Funding certainty deserves separate attention. Money payable only after future milestones is not the same as cash available at completion. A business should test whether the initial subscription provides enough runway to reach those milestones, including reasonable headroom for delays. The commercial consequences of missing a condition may matter more than a small improvement in the initial subscription price.

Negotiation can also change the balance between immediate dilution and future financing risk. Raising less now preserves a larger percentage initially, but may leave the company needing another round before it has demonstrated meaningful progress. Raising more can provide resilience while increasing current dilution. A valuation does not decide the business strategy, but it can make these trade-offs explicit and test whether the proposed plan is financially coherent.

The practical comparison is therefore not simply ‘Which investor offers the largest number?’ It is ‘What cash is committed, what must happen to receive it, what rights are granted, and what do existing shareholders retain across plausible outcomes?’ Strategic benefits may also matter, but claimed introductions or commercial opportunities should be distinguished from contractual commitments and supported assumptions.

Reference framework:[1] IVSC[4] IPEV[5] ICAEW

Start with a reliable financial record and an explanation of current trading. Annual accounts alone may be too dated to support a live negotiation. Management accounts should reconcile sensibly with the statutory position, and material changes should be explained. The valuer needs to understand exceptional items, revenue recognition, customer concentration and any differences between reported profit and cash generated.

Provide a funding plan that links expenditure to commercial objectives. It should explain how much capital is required, when it will be spent, what milestones it is intended to achieve and whether further rounds are expected. Forecasts should include a cash-flow view and identifiable assumptions. A presentation showing rapid revenue growth without the supporting staffing, delivery capacity or working capital leaves important valuation questions unanswered.

The legal and ownership information is equally important. A current cap table should distinguish issued shares from options, warrants and instruments that may convert. Articles, shareholders’ agreements and proposed investment terms help identify the rights being valued. If documents are still being negotiated, the report should state which version and assumptions it uses, with material changes referred back for review.

Finally, agree the instructions before analysis begins: purpose, valuation date, relevant share classes, intended users and required output. Identify whether the assessment supports negotiation, internal decision-making, reporting or another defined use. A structured information pack makes the process faster and reduces repeated questions, but gaps should be acknowledged rather than filled with unsupported certainty.

• Financial evidence: recent accounts, management reporting, cash and debt schedules, and explanations of material adjustments.
• Commercial evidence: customer concentration, contracts, pipeline quality, retention information and dependencies.
• Funding evidence: integrated forecasts, use of funds, milestone timetable and downside cash requirements.
• Ownership evidence: current and fully diluted cap tables, share rights, options, convertibles and proposed investment documents.

Reference framework:[1] IVSC[4] IPEV[5] ICAEW

An independent XVAL valuation provides an expert-led assessment of the business and the specific ownership interest, rather than an automated calculator result. The work connects financial evidence, commercial prospects and share rights to a documented conclusion. For a fundraising, that gives owners and advisers a clearer starting point for negotiation and a way to explain the assumptions behind the proposed valuation.

The analysis can distinguish the value question from the transaction mechanics. That includes separating pre-money and post-money figures, reviewing the ownership implications of the proposed subscription, and identifying where different share rights limit direct comparisons. Where appropriate to the agreed scope, scenarios can show how changes in performance, funding needs or transaction terms affect the assessment. Assumptions and limitations remain visible.

Human judgement is especially important where evidence is incomplete or the business is changing quickly. XVAL’s specialists can discuss information gaps with management and work alongside the company’s accountants and solicitors, while maintaining an independent valuation role. The resulting report documents the relevant methods, evidence and reasoning; it does not guarantee investor acceptance, regulatory agreement or a particular transaction outcome.

XVAL reviews enquiries the same working day so that the purpose, available information and timetable can be assessed promptly. Delivery timing is agreed around the scope and readiness of the evidence, with a focus on progressing the work quickly without bypassing necessary analysis. The objective is a clear, usable valuation that supports an informed decision, not a headline figure detached from the terms of the investment.

Reference framework:[1] IVSC[5] ICAEW

Questions owners ask

Frequently asked questions

Reference desk

Sources & further reading

Legislation states the legal provisions; HMRC manuals describe HMRC’s guidance. Professional standards and research guides inform valuation practice. Illustrations and commercial checklists above are explanatory analysis, not prescribed legal formulas or market benchmarks.

1. [1]IVSC — International Valuation Standards
2. [2]TCGA 1992, section 272 — Market value
3. [3]HMRC — Get a share scheme valuation
4. [4]IPEV — Valuation Guidelines
5. [5]ICAEW — Business and share valuation
6. [6]FRC — FRS 102

This article provides general technical information, not legal, tax or investment advice. Its application depends on the facts, the valuation purpose and rules in force at the relevant date. A reference to a professional body does not imply XVAL accreditation or endorsement. All numerical examples are hypothetical, not XVAL fees, client results or market evidence.